SEARCH

SEARCH BY CITATION

REFERENCES

  • Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2002. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: Therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 37: 831836.
  • Akuta N, Suzuki F, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003. Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy. J Med Virol 69: 376383.
  • Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. 2005a. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus. Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 40: 688696.
  • Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005b. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interferon–ribavirin combination therapy. Intervirology 48: 372380.
  • Alexander WS. 2002. Suppressors of cytokine signaling (SOCS) in the immune system. Nat Rev Immunol 2: 410416.
  • Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L, Antonelli L, Pistello M, Dianzai F. 1999. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic hepatitis C to IFN-α therapy. J Interferon Cytokine Res 19: 243251.
  • Auernhammer CJ, Melmed S. 2001. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest 108: 17351740.
  • Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. 2003. Expression of hepatitis C virus proteins inhibits interferon α signaling in the liver of transgenic mice. Gastroenterology 124: 14651475.
  • Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Häussinger D. 2003. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17: 488490.
  • Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, Morinaga T, Kumada H. 1993. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 8: 150156.
  • D'Alessandro AM, Kalayouglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, Pirsch JD, Hafez GR, Lorentzen D, Belzer FO. 1991. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 51: 157163.
  • de Lucas S, Bartolome J, Carreno V. 2005. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 191: 9399.
  • Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19: 15131520.
  • Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. J Clin Invest 96: 224230.
  • Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 7781.
  • Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975982.
  • Fujimoto M, Naka T. 2003. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24: 659666.
  • Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230: 217227.
  • Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M. 1999. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29: 11241130.
  • Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87: 95249528.
  • Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339: 237238.
  • Lalvakolanu DV. 2003. Alternate interferon signaling pathways. Pharmacol Ther 100: 129.
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358: 958965.
  • Melén K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I. 2004. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol 73: 536547.
  • Ronni T, Matikainen S, Lehtonen A, Palvimo J, Dellis J, Van Eylen F, Goetschy JF, Horisberger M, Content J, Julkunen I. 1998. The proximal interferon-stimulated response elements are essential for interferon responsiveness: A promoter analysis of the antiviral MxA gene. J Interferon Cytokine Res 18: 773781.
  • Song MM, Shuai K. 1998. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273: 3505635062.
  • Stoiber D, Kovarik P, Cohney S, Johnston JA, Steinlein P, Decker T. 1999. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J Immunol 163: 26402647.
  • Vlotides G, Sörensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, Auernhammer CJ. 2004. SOCS-1 and SCOS-3 inhibit IFN-α-induced expression of the antiviral 2,5-OAS and MxA. Biochem Biophys Res Commun 320: 10071014.
  • Wang Q, Floyd-Smith G. 1997. The p69/71 2-5A synthetase promoter contains multiple regulatory elements required for interferon-alpha-induced expression. DNA Cell Biol 16: 13851394.